Fundación CENIT para la Investigación en Neurociencias
Welcome,         Profile    Billing    Logout  
 19 Trials 
50 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, Robert L
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PREMIER, NCT05214105: The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Recruiting
N/A
400
US
Biospecimen/DNA collection and analysis
University of Tennessee, National Heart, Lung, and Blood Institute (NHLBI), University of Illinois at Chicago, University of Memphis, University of North Carolina, Charlotte, Wake Forest University, University of North Carolina, Chapel Hill
Sickle Cell Disease, Kidney Diseases, Chronic
01/26
01/26
Wang, Hao
TNK-PLUS, NCT06221371: Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

Recruiting
3
390
RoW
rhTNK-tPA, Tenecteplase, direct EVT
Beijing Tiantan Hospital, Linyi People's Hospital
Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment
12/24
05/25
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Terminated
2
28
RoW
Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Breast Cancer
01/23
01/23
NCT04892498: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Recruiting
2
66
RoW
Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF, IL-2
Second Affiliated Hospital of Soochow University
Advanced Refractory Solid Tumors
08/23
08/24
NCT03478358: Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Recruiting
1
60
RoW
177Lu-DOTA-EB-TATE 1, 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE 2, 177Lu-DOTA-EB-TATE 3, 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine), 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
Peking Union Medical College Hospital
Neuroendocrine Tumors
12/22
05/23
NCT04748068: Use of Glidesheath Slender to Reduce Radial Artery Occlusion Following 7 French Transradial Coronary Intervention

Not yet recruiting
N/A
500
RoW
7-Fr Glidesheath Slender, Glidesheath Slender, Terumo, Tokyo, Japan, Cordis 7-Fr radial sheath
China National Center for Cardiovascular Diseases
Radial Artery Occlusion, Coronary Artery Disease
05/21
05/21
NCT04881292: RF Based QIMT & QAS Study on Chinese Adults

Recruiting
N/A
3500
RoW
Tang-Du Hospital, Esaote (Shenzhen) Medical Equipment Co. Ltd, The First Affiliated Hospital, Zhejiang University School of Medicine, Shannxi Provincial People's Hospital, Shengjing Hospital, First Hospital of China Medical University, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Beijing University of Chinese Medicine Third Affiliated Hospital, The First Affiliated Hospital of Shanxi Medical University, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, The First Hospital of Jilin University, The Afffiliated Hospital of Guizhou Medical University, Yan An Hospital Affiliated to Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Third Xiangya Hospital of Central South University, Ruijin Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Anhui Medical University, The First Affiliated Hospital of USTC, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Xinjiang Medical University, Hospital of Northwestern Polytechnical University, GEM Flower Xian Changqing Staff Hospital, Xi'an Central Hospital, The Second Affiliated Hospital of Xi'an Medical University, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Karamay Central Hospital of Xinjiang, The Fourth Affiliated Hospital of Xinjiang Medical University, Xi'an No.1 Hospital, Xianyang Hospital of Yan'an University, General Hospital of Xinjiang Production and Construction Corps, Air Force Medical Center
Healthy, Adults, Carotid Intima-media Thickness, Vascular Stiffness, Chinese
05/22
05/22
NCT06014476: Psychological Symptoms and Burden in Caregivers of Patients With Disorders of Consciousness

Completed
N/A
256
RoW
questionnaires, Coma Recovery Scale-Revised (CRS-R)
Hangzhou Normal University
Psychological Distress, Anxiety Depression, Burden, Caregiver, Disorders of Consciousness
10/22
10/22
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study)

Active, not recruiting
N/A
88
RoW
WeFlow-Arch Modeler Embedded Branch Stent Graft System
Hangzhou Endonom Medtech Co., Ltd.
Aortic Arch Aneurysm
02/25
02/29
NCT06143540: Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
N/A
30
RoW
Sichuan Provincial People's Hospital
Interstitial Lung Disease
05/24
07/24
NCT05944198: Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis

Completed
N/A
40
RoW
Sichuan Provincial People's Hospital
Rheumatoid Arthritis
02/24
02/24
PUTHRC-001, NCT05070832: Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC

Not yet recruiting
N/A
142
NA
Deep Hyperthermia
Peking University Third Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital
Hyperthermia, Radiotherapy
12/23
12/24
NCT05976620: Clinical Study of 18F-FAPI-RGD in Breast Tumors

Completed
N/A
30
RoW
Sichuan Provincial People's Hospital
Breast Tumors
12/23
02/24
NCT05976607: Clinical Study of 18F -FAPI-RGD in Renal Tumor

Completed
N/A
35
RoW
Sichuan Provincial People's Hospital
Renal Tumor
01/24
02/24
COSTAR, NCT06583070: SABR Combined with Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

Recruiting
N/A
300
RoW
Radiation therapy, Targeted and immunotherapy
Peking University First Hospital, Peking University Third Hospital
Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
03/27
03/27
NCT06833645: [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

Recruiting
N/A
280
RoW
molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)
Sichuan Provincial People's Hospital
Alzheimer's Disease
02/25
02/25
MATESHIP, NCT05290454: mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients

Recruiting
N/A
342
RoW
mNGS-guided treatment
Qilu Hospital of Shandong University, Jinan Central Hospital
Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia, Infections
06/24
09/24
NCT06094530: 18F-FAPI-RGD PET/CT in Various Tumor Types

Recruiting
N/A
100
RoW
Sichuan Provincial People's Hospital
Neoplasms
09/24
10/24
NCT06120413: 18F-LN1 PET/CT in Urothelial Carcinomas

Recruiting
N/A
30
RoW
Sichuan Provincial People's Hospital
Urothelial Carcinoma
09/24
10/24
CIVAP, NCT06834971: Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting
N/A
476
RoW
Colistimethate sodium (CMS)
Qilu Hospital of Shandong University
Pneumonia, Ventilator-Associated
12/25
03/26
FLORA-01, NCT05730595: Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

Not yet recruiting
N/A
550
RoW
lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Colorectal Neoplasms, Fluorescence, Lymph Node Excision
12/26
06/27
ENDURE-APAC, NCT05578300: Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific

Recruiting
N/A
350
RoW
Thrombus analyses, Imaging assessment
Chinese University of Hong Kong, Linyi People's Hospital
Ischemic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases, Major Adverse Cardiovascular Event
10/32
12/32
BHC-C, NCT05961748: Registry of Multicenter Brain-Heart Comorbidity in China

Recruiting
N/A
100000
RoW
Multi-disciplinary assessment
Beijing Tiantan Hospital
Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure, Aortic Diseases, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Cerebral Infarction, Occlusion and Stenosis of Precerebral Arteries, Occlusion and Stenosis of Cerebellar Arteries, Cerebral Aneurysm, Moyamoya Disease, Arteriovenous Malformation of Cerebral Vessels
12/32
12/32
NCT05348902: Locked-in Syndrome Caused by Pulmonary Arteriovenous Malformation: A Case Report

Recruiting
N/A
1
RoW
In this study, only cases were collected and reported without any intervention or adverse reactions
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locked-In Syndrome；Pulmonary Arteriovenous Malformation
06/22
06/22
Knoble, Jeanna
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Sun, Ping
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
663
RoW
Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
05/27
05/27
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
NCT05774873: IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
128
RoW
IBI334 D, IBI334 C, IBI334 A, IBI334 B, IBI334 F, IBI334 E
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumors
10/25
06/26
Sharma, Ruby
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Casalnuovo, Mónica Lis
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Casalnuovo, Monica Lis
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Hehn, Natalia Laura Baltz
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
Dougherty, Miho
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, Robert L
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PREMIER, NCT05214105: The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Recruiting
N/A
400
US
Biospecimen/DNA collection and analysis
University of Tennessee, National Heart, Lung, and Blood Institute (NHLBI), University of Illinois at Chicago, University of Memphis, University of North Carolina, Charlotte, Wake Forest University, University of North Carolina, Chapel Hill
Sickle Cell Disease, Kidney Diseases, Chronic
01/26
01/26
Wang, Hao
TNK-PLUS, NCT06221371: Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

Recruiting
3
390
RoW
rhTNK-tPA, Tenecteplase, direct EVT
Beijing Tiantan Hospital, Linyi People's Hospital
Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment
12/24
05/25
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Terminated
2
28
RoW
Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Breast Cancer
01/23
01/23
NCT04892498: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Recruiting
2
66
RoW
Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF, IL-2
Second Affiliated Hospital of Soochow University
Advanced Refractory Solid Tumors
08/23
08/24
NCT03478358: Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Recruiting
1
60
RoW
177Lu-DOTA-EB-TATE 1, 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE 2, 177Lu-DOTA-EB-TATE 3, 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine), 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
Peking Union Medical College Hospital
Neuroendocrine Tumors
12/22
05/23
NCT04748068: Use of Glidesheath Slender to Reduce Radial Artery Occlusion Following 7 French Transradial Coronary Intervention

Not yet recruiting
N/A
500
RoW
7-Fr Glidesheath Slender, Glidesheath Slender, Terumo, Tokyo, Japan, Cordis 7-Fr radial sheath
China National Center for Cardiovascular Diseases
Radial Artery Occlusion, Coronary Artery Disease
05/21
05/21
NCT04881292: RF Based QIMT & QAS Study on Chinese Adults

Recruiting
N/A
3500
RoW
Tang-Du Hospital, Esaote (Shenzhen) Medical Equipment Co. Ltd, The First Affiliated Hospital, Zhejiang University School of Medicine, Shannxi Provincial People's Hospital, Shengjing Hospital, First Hospital of China Medical University, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Beijing University of Chinese Medicine Third Affiliated Hospital, The First Affiliated Hospital of Shanxi Medical University, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, The First Hospital of Jilin University, The Afffiliated Hospital of Guizhou Medical University, Yan An Hospital Affiliated to Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Third Xiangya Hospital of Central South University, Ruijin Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Anhui Medical University, The First Affiliated Hospital of USTC, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Xinjiang Medical University, Hospital of Northwestern Polytechnical University, GEM Flower Xian Changqing Staff Hospital, Xi'an Central Hospital, The Second Affiliated Hospital of Xi'an Medical University, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Karamay Central Hospital of Xinjiang, The Fourth Affiliated Hospital of Xinjiang Medical University, Xi'an No.1 Hospital, Xianyang Hospital of Yan'an University, General Hospital of Xinjiang Production and Construction Corps, Air Force Medical Center
Healthy, Adults, Carotid Intima-media Thickness, Vascular Stiffness, Chinese
05/22
05/22
NCT06014476: Psychological Symptoms and Burden in Caregivers of Patients With Disorders of Consciousness

Completed
N/A
256
RoW
questionnaires, Coma Recovery Scale-Revised (CRS-R)
Hangzhou Normal University
Psychological Distress, Anxiety Depression, Burden, Caregiver, Disorders of Consciousness
10/22
10/22
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study)

Active, not recruiting
N/A
88
RoW
WeFlow-Arch Modeler Embedded Branch Stent Graft System
Hangzhou Endonom Medtech Co., Ltd.
Aortic Arch Aneurysm
02/25
02/29
NCT06143540: Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
N/A
30
RoW
Sichuan Provincial People's Hospital
Interstitial Lung Disease
05/24
07/24
NCT05944198: Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis

Completed
N/A
40
RoW
Sichuan Provincial People's Hospital
Rheumatoid Arthritis
02/24
02/24
PUTHRC-001, NCT05070832: Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC

Not yet recruiting
N/A
142
NA
Deep Hyperthermia
Peking University Third Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital
Hyperthermia, Radiotherapy
12/23
12/24
NCT05976620: Clinical Study of 18F-FAPI-RGD in Breast Tumors

Completed
N/A
30
RoW
Sichuan Provincial People's Hospital
Breast Tumors
12/23
02/24
NCT05976607: Clinical Study of 18F -FAPI-RGD in Renal Tumor

Completed
N/A
35
RoW
Sichuan Provincial People's Hospital
Renal Tumor
01/24
02/24
COSTAR, NCT06583070: SABR Combined with Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

Recruiting
N/A
300
RoW
Radiation therapy, Targeted and immunotherapy
Peking University First Hospital, Peking University Third Hospital
Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
03/27
03/27
NCT06833645: [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

Recruiting
N/A
280
RoW
molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)
Sichuan Provincial People's Hospital
Alzheimer's Disease
02/25
02/25
MATESHIP, NCT05290454: mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients

Recruiting
N/A
342
RoW
mNGS-guided treatment
Qilu Hospital of Shandong University, Jinan Central Hospital
Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia, Infections
06/24
09/24
NCT06094530: 18F-FAPI-RGD PET/CT in Various Tumor Types

Recruiting
N/A
100
RoW
Sichuan Provincial People's Hospital
Neoplasms
09/24
10/24
NCT06120413: 18F-LN1 PET/CT in Urothelial Carcinomas

Recruiting
N/A
30
RoW
Sichuan Provincial People's Hospital
Urothelial Carcinoma
09/24
10/24
CIVAP, NCT06834971: Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting
N/A
476
RoW
Colistimethate sodium (CMS)
Qilu Hospital of Shandong University
Pneumonia, Ventilator-Associated
12/25
03/26
FLORA-01, NCT05730595: Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

Not yet recruiting
N/A
550
RoW
lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Colorectal Neoplasms, Fluorescence, Lymph Node Excision
12/26
06/27
ENDURE-APAC, NCT05578300: Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific

Recruiting
N/A
350
RoW
Thrombus analyses, Imaging assessment
Chinese University of Hong Kong, Linyi People's Hospital
Ischemic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases, Major Adverse Cardiovascular Event
10/32
12/32
BHC-C, NCT05961748: Registry of Multicenter Brain-Heart Comorbidity in China

Recruiting
N/A
100000
RoW
Multi-disciplinary assessment
Beijing Tiantan Hospital
Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure, Aortic Diseases, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Cerebral Infarction, Occlusion and Stenosis of Precerebral Arteries, Occlusion and Stenosis of Cerebellar Arteries, Cerebral Aneurysm, Moyamoya Disease, Arteriovenous Malformation of Cerebral Vessels
12/32
12/32
NCT05348902: Locked-in Syndrome Caused by Pulmonary Arteriovenous Malformation: A Case Report

Recruiting
N/A
1
RoW
In this study, only cases were collected and reported without any intervention or adverse reactions
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locked-In Syndrome；Pulmonary Arteriovenous Malformation
06/22
06/22
Knoble, Jeanna
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Sun, Ping
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
663
RoW
Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
05/27
05/27
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
NCT05774873: IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
128
RoW
IBI334 D, IBI334 C, IBI334 A, IBI334 B, IBI334 F, IBI334 E
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumors
10/25
06/26
Sharma, Ruby
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Casalnuovo, Mónica Lis
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Casalnuovo, Monica Lis
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Hehn, Natalia Laura Baltz
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
Dougherty, Miho
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options